Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB announced the outcome of its rights issue, which raised approximately SEK 115.7 million before costs. The rights issue was subscribed to about 61.1% with and without subscription rights, and the company plans to use the proceeds to strengthen its financial position and prepare for the next stage of its drug development projects, enhancing their appeal for potential partnerships.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a biotechnology company focused on the development of novel treatments for neurological disorders. The company primarily works on drug projects that aim to address unmet medical needs, enhancing their commercial attractiveness through strategic partnerships and licensing agreements.
Average Trading Volume: 69,188
Current Market Cap: SEK323.6M
Learn more about IRLAB.A stock on TipRanks’ Stock Analysis page.